Literature DB >> 22644589

Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.

Nicolas Tournier1, Salvatore Cisternino, Marie-Anne Peyronneau, Sébastien Goutal, Frédéric Dolle, Jean-Michel Scherrmann, Michel Bottlaender, Wadad Saba, Héric Valette.   

Abstract

PURPOSE: Several in vivo studies have found that the 5-HT(1A) PET radioligand (18)F-MPPF is a substrate of rodent P-glycoprotein (P-gp). However, in vitro assays suggest that MPPF is not a substrate of human P-gp. We have now tested the influence of inhibiting P-gp on the brain kinetics of (18)F-MPPF in mice and non-human primates.
METHODS: We measured the peripheral kinetics (arterial input function, metabolism, free fraction in plasma (f(P))) during (18)F-MPPF brain PET scanning in baboons with or without cyclosporine A (CsA) infusion. We measured (3)H-MPPF transport at the mouse BBB using in situ brain perfusion in P-gp/Bcrp deficient mice and after inhibiting P-gp with PSC833.
RESULTS: There was an unexpected 1.9-fold increase in brain area under the curve in CsA-treated baboons (n = 4), with no change in radiometabolite-corrected arterial input. However, total volume of distribution corrected for f(P) (V(T)/f(P)) remained unchanged. In situ brain perfusion showed that P-gp restricted the permeability of the mouse BBB to (3)H-MPPF while Bcrp did not.
CONCLUSION: These and previous in vitro results suggest that P-gp may not influence the permeability of human BBB to (18)F-MPPF. However, CsA treatment increased (18)F-MPPF free fraction, which is responsible for a misleading, P-gp unrelated enhanced brain uptake.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644589     DOI: 10.1007/s11095-012-0776-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  42 in total

1.  Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY.

Authors:  Jeih-San Liow; Shuiyu Lu; Julie A McCarron; Jinsoo Hong; John L Musachio; Victor W Pike; Robert B Innis; Sami S Zoghbi
Journal:  Synapse       Date:  2007-02       Impact factor: 2.562

2.  In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.

Authors:  Kiichi Ishiwata; Kazunori Kawamura; Kazuhiko Yanai; N Harry Hendrikse
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 3.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

4.  Liquid chromatography-tandem mass spectrometry identification of metabolites of three phenylcarboxyl derivatives of the 5-HT(1A) antagonist, N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl) trans-4-fluorocyclohexanecarboxamide (FCWAY), produced by human and rat hepatocytes.

Authors:  Ying Ma; Lixin Lang; Dale O Kiesewetter; William C Eckelman
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-15       Impact factor: 3.205

5.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

6.  In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein.

Authors:  Chunbo Zhang; Zhong Zuo; Patrick Kwan; Larry Baum
Journal:  Epilepsia       Date:  2011-06-21       Impact factor: 5.864

7.  Modeling [18 F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection.

Authors:  Nicolas Costes; Isabelle Merlet; Luc Zimmer; Franck Lavenne; Luc Cinotti; Jacques Delforge; André Luxen; Jean-François Pujol; Didier Le Bars
Journal:  J Cereb Blood Flow Metab       Date:  2002-06       Impact factor: 6.200

8.  Avoiding barriers to PET radioligand development: cellular assays of brain efflux transporters.

Authors:  Matthew D Hall; Victor W Pike
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

9.  Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs.

Authors:  Richard E Carson; Yanjun Wu; Lixin Lang; Ying Ma; Margaret G Der; Peter Herscovitch; William C Eckelman
Journal:  J Cereb Blood Flow Metab       Date:  2003-02       Impact factor: 6.200

10.  18F-ZW-104: a new radioligand for imaging neuronal nicotinic acetylcholine receptors--in vitro binding properties and PET studies in baboons.

Authors:  Héric Valette; Yingxiang Xiao; Marie-Anne Peyronneau; Annelaure Damont; Alan P Kozikowski; Zhi-Liang Wei; Michael Kassiou; Kenneth J Kellar; Frédéric Dollé; Michel Bottlaender
Journal:  J Nucl Med       Date:  2009-08       Impact factor: 10.057

View more
  9 in total

1.  First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.

Authors:  Ansel T Hillmer; Dustin W Wooten; Alisha K Bajwa; Andrew T Higgins; Patrick J Lao; Tobey J Betthauser; Todd E Barnhart; Howard A Rowley; Charles K Stone; Sterling C Johnson; Jogeshwar Mukherjee; Bradley T Christian
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

Review 2.  Quantitative Rodent Brain Receptor Imaging.

Authors:  Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

Review 3.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

4.  Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.

Authors:  Nicolas Tournier; Wadad Saba; Sébastien Goutal; Philippe Gervais; Héric Valette; Jean-Michel Scherrmann; Michel Bottlaender; Salvatore Cisternino
Journal:  AAPS J       Date:  2015-02-26       Impact factor: 4.009

5.  Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?

Authors:  Louise Breuil; Solène Marie; Sébastien Goutal; Sylvain Auvity; Charles Truillet; Wadad Saba; Oliver Langer; Fabien Caillé; Nicolas Tournier
Journal:  J Cereb Blood Flow Metab       Date:  2021-09-09       Impact factor: 6.960

Review 6.  Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Authors:  Stina Syvänen; Jonas Eriksson
Journal:  ACS Chem Neurosci       Date:  2012-12-04       Impact factor: 4.418

7.  P-Glycoprotein, not BCRP, Limits the Brain Uptake of [(18)F]Mefway in Rodent Brain.

Authors:  Jae Yong Choi; Jin Sook Song; Minkyung Lee; Woon-Ki Cho; Jin Chung; Chul Hyoung Lyoo; Chul Hoon Kim; Jiae Park; Kyo Chul Lee; Kyeong Min Kim; Jee Hae Kang; Myung Ae Bae; Young Hoon Ryu
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

Review 8.  In vitro, in vivo and in silico models of drug distribution into the brain.

Authors:  Scott G Summerfield; Kelly C Dong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

9.  Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate 11C-Metoclopramide Assessed with PET Imaging in Humans.

Authors:  Nicolas Tournier; Martin Bauer; Verena Pichler; Lukas Nics; Eva-Maria Klebermass; Karsten Bamminger; Peter Matzneller; Maria Weber; Rudolf Karch; Fabien Caillé; Sylvain Auvity; Solène Marie; Walter Jäger; Wolfgang Wadsak; Marcus Hacker; Markus Zeitlinger; Oliver Langer
Journal:  J Nucl Med       Date:  2019-01-10       Impact factor: 11.082

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.